# EDGAR Filing Document

**Accession Number:** 0002021793
**File Stem:** 0000950103-26-005723
**Filing Date:** 2026-4
**Character Count:** 8140
**Document Hash:** b7a0e081adc3cf388a695c80d2625389
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950103-26-005723.hdr.sgml**: 20260416

**ACCESSION NUMBER**: 0000950103-26-005723

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260412

**FILED AS OF DATE**: 20260415

**DATE AS OF CHANGE**: 20260415

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ASE Test, Inc.
- **CENTRAL INDEX KEY:** 0002021793

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** F5
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41461
- **FILM NUMBER:** 26862475

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10, WEST 5TH STREET
- **STREET 2:** NANZIH DISTRICT
- **CITY:** KAOHSIUNG
- **PROVINCE COUNTRY:** F5
- **ZIP:** 811
- **BUSINESS PHONE:** 886-7-363-6641

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 10, WEST 5TH STREET
- **STREET 2:** NANZIH DISTRICT
- **CITY:** KAOHSIUNG
- **PROVINCE COUNTRY:** F5
- **ZIP:** 811
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ainos, Inc.
- **CENTRAL INDEX KEY:** 0001014763
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 751974352
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3050 POST OAK BLVD,
- **STREET 2:** SUITE 510-T80
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056
- **BUSINESS PHONE:** (281) 898-6586

**MAIL ADDRESS:**
- **STREET 1:** 3050 POST OAK BLVD,
- **STREET 2:** SUITE 510-T80
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARILLO BIOSCIENCES INC
- **DATE OF NAME CHANGE:** 19960516

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ASE Test, Inc.<br><sub>(Last) (First) (Middle)</sub><br>10 WEST FIFTH STREET, NANZIH DISTRICT<br><sub>(Street)</sub><br>KAOHSIUNG, TAIWAN 00000<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-04-12 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [X] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Ainos, Inc. [ AIMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |  |  |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 6% Convertible Note due 2027 (previously due 2025) | $22.5 | 2026-04-12 |  | P |  | 5994 |  | <sup>(2)</sup> | <sup>(2)</sup> | Common Stock, par value $0.01 | 5994 | <sup>(2)(3)</sup> | 105868 | D<sup>(1)</sup> |  |

---

### Footnotes:

(1) The convertible notes with respect to shares of common stock, $0.01 par value (the "Common Stock"), of Ainos, Inc., a Texas corporation (the "Issuer") reported herein are directly held by ASE Test, Inc., an indirectly wholly-owned subsidiary of ASE Technology Holding Co., Ltd. Accordingly, ASE Technology Holding Co., Ltd. is reporting indirect ownership of the securities held by ASE Test, Inc.

(2) As previously reported, the Issuer and ASE Test, Inc. entered into a Convertible Note and Warrant Purchase Agreement, dated March 13, 2023 (the "2023 Convertible Note"), pursuant to which the Issuer issued convertible promissory notes to ASE Test, Inc. in the principal amount of $2,000,000 (the "Principal Amount") and six percent (6%) compounded interest of which was due on March 13, 2025. On March 10, 2025, the Issuer and ASE Test, Inc. entered into an amendment to the 2023 Convertible Note (the "Amended Convertible Note") to extend the maturity date to March 12, 2027 and change the conversion price from $7.50 per share to a conversion price equal to the lower of (a) $7.50 per share and (b) the higher of (x) the average closing price per share of the Issuer's common stock for the period of thirty (30) trading days prior to the day when the noteholder exercises the conversion right or (y) $4.50, subject to anti-dilutive adjustment as set forth in the Amended Convertible Note.

(3) As a result of the five-for-one reverse stock split effected by the Issuer on June 30, 2025, the conversion price is now the lower of (a) $37.50 per share and (b) the higher of (x) the average closing price per share of the Issuer's common stock for the period of thirty (30) trading days prior to the day when the noteholder exercises the conversion right or (y) $22.50, subject to anti-dilutive adjustment as set forth in the Amended Convertible Note.

**Signature:** /s/ Alan Li, By: ASE Test, Inc., By: Alan Li, authorized signatory of ASE Test, Inc.  
**Date:** 2026-04-15

**Signature:** /s/ Joseph Tung, authorized signatory of ASE Technology Holding Co., Ltd.  
**Date:** 2026-04-15

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**